Iqbal J. Hussain - 30 Jan 2026 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role: Chief Legal Officer
Signature: /s/ Raphael Deferiere, attorney-in-fact
Issuer symbol: CNTA
Transactions as of: 30 Jan 2026
Net transactions value: -$1,196,072
Form type: 4
Filing time: 03 Feb 2026, 18:59:07 UTC
Previous filing: 18 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
HUSSAIN IQBAL J	Chief Legal Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE, UNITED KINGDOM	/s/ Raphael Deferiere, attorney-in-fact	03 Feb 2026	0001862050

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CNTA	Ordinary Shares	Sale	$25,261	-1,010	-0.96%	$25.01	104,376	30 Jan 2026	Direct	F1, F2
transaction	CNTA	Ordinary Shares	Tax liability	$191,155	-7,780	-7.5%	$24.57	96,596	01 Feb 2026	Direct	F1, F3
transaction	CNTA	Ordinary Shares	Sale	$979,657	-38,951	-40%	$25.15	57,645	02 Feb 2026	Direct	F1, F4
transaction	CNTA	Ordinary Shares	Award	$0	+40,000	+69%	$0.000000	97,645	02 Feb 2026	Direct	F1, F5
transaction	CNTA	Ordinary Shares	Award	$0	+20,000	+20%	$0.000000	117,645	02 Feb 2026	Direct	F1, F6
holding	CNTA	Ordinary Shares						5,500	30 Jan 2026	By spouse	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CNTA	Share Option (right to buy)	Award	$0	+160,000		$0.000000	160,000	02 Feb 2026	Ordinary Shares	160,000	$25.19	Direct	F1, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3	Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5	The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 2, 2027.
F6	The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest on February 2, 2027.
F7	1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 2, 2026.